These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2567211)

  • 21. Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.
    Nishimura T; Nakamura Y; Takeuchi Y; Gao XH; Tokuda Y; Okumura K; Habu S
    Jpn J Cancer Res; 1991 Nov; 82(11):1207-10. PubMed ID: 1836455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.
    Massaro AF; Schoof DD; Rubinstein A; Zuber M; Leonard-Vidal FJ; Eberlein TJ
    Cancer Res; 1990 May; 50(9):2587-92. PubMed ID: 2139356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
    Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
    Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell surface phenotype of two cloned populations of bovine lymphocytes displaying non-specific cytotoxic activity.
    Goddeeris BM; Dunlap S; Bensaid A; MacHugh ND; Morrison WI
    Vet Immunol Immunopathol; 1991 Jan; 27(1-3):195-9. PubMed ID: 1826981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
    Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
    Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition.
    Moretta A; Bottino C; Pende D; Tripodi G; Tambussi G; Viale O; Orengo A; Barbaresi M; Merli A; Ciccone E
    J Exp Med; 1990 Dec; 172(6):1589-98. PubMed ID: 2147946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and utilization of chymotrypsin-like but not trypsin-like serine protease enzymes by nonspecific T killer cells activated by anti-CD3 monoclonal antibody.
    Kaiser M; Hoskin DW
    Cell Immunol; 1992 Apr; 141(1):84-98. PubMed ID: 1532539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activation of lymphocytes from nonsmall cell cancer patients by interleukin 2 and anti-CD3 antibody.
    Pisani RJ; Leibson PJ; McKean DJ
    Clin Immunol Immunopathol; 1989 Mar; 50(3):348-63. PubMed ID: 2537164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD3 antibody-treated mice: in vivo induction of cytolytic activity and TNF production by lung leukocytes.
    Stanková J
    Int J Cancer; 1992 May; 51(2):259-65. PubMed ID: 1533202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD3 antibody-induced activated killer cells: cytokines as the additional signals for activation of killer cells in effector phase to mediate slow lysis.
    Ting CC; Hargrove ME
    Cell Immunol; 1991 Jul; 135(2):273-84. PubMed ID: 1828008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients.
    Chen YM; Yang WK; Whang-Peng J; Tsai WY; Hung YM; Yang DM; Lin WC; Perng RP; Ting CC
    J Immunother; 1997 Sep; 20(5):354-64. PubMed ID: 9336742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo.
    Crossland KD; Lee VK; Chen W; Riddell SR; Greenberg PD; Cheever MA
    J Immunol; 1991 Jun; 146(12):4414-20. PubMed ID: 1674958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
    Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML
    Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting of "T" lymphocytes against human hepatoma cells by a bispecific monoclonal antibody: role of different lymphocyte subsets.
    Chen Q; Sun P; Prigione I; Xie H; Ferrini S
    Tumori; 1992 Apr; 78(2):79-86. PubMed ID: 1326141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surface molecules involved in the activation and regulation of T or natural killer lymphocytes in humans.
    Moretta A; Ciccone E; Pantaleo G; Tambussi G; Bottino C; Melioli G; Mingari MC; Moretta L
    Immunol Rev; 1989 Oct; 111():145-75. PubMed ID: 2697680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
    Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
    J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T lymphocytes displaying major histocompatibility complex-unrestricted cytotoxicity after activation by K46M, a mitogenic monoclonal antibody against leucoagglutinin-reactive human T lymphocyte surface components.
    Vargas-Cortes M; Berzins T; Hammarström ML; Hammarström S; Perlmann P
    Scand J Immunol; 1987 Oct; 26(4):397-407. PubMed ID: 3500499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.
    Nijhuis EW; vd Wiel-van Kemenade E; Figdor CG; van Lier RA
    Cancer Immunol Immunother; 1990; 32(4):245-50. PubMed ID: 2175673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.